The newest drugs to target chronic lymphocytic leukaemia (CLL) include the inhibitors of the intracellular B‐cell receptor signalling (BCR inhibitor)1 and the BCL2 inhibitor venetoclax.2, 3 B‐cell receptor signalling inhibitors incorporate the direct BTK inhibitor ibrutinib and the inhibitor of PI3K‐delta,4 a BTK downstream effector, idelalisib. Here, BTK is linked to B-cell chronic lymphocytic leukemia.